Daiichi Sankyo

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved. AstraZeneca’s big bet on a Daiichi Sankyo-developed HER2-targeting antibody-drug conjugate looks like its about to pay off, after delivering ... AZ and Daiichi Sankyo are looking at a possible approval for

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo

US-based biotech is arguing the legal action is improper. Seattle Genetics has asked a court to dismiss a lawsuit brought a few weeks ago by Japan’s Daiichi Sankyo centring ... The two companies previously collaborated on ADC drug development between

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Daiichi said today that Seattle Genetics is “claiming certain intellectual property rights related to Daiichi Sankyo’s ADC products”, a stance which it insists is “without merit”. ... The original agreement between the companies cover ADCs

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Meanwhile, Daiichi Sankyo has said it will concentrate on first-line use of quizartinib after being turned down by regulators in Europe and the US, and says it recently completed enrolment ... There are differences between the two drugs, as quizartinib

Seattle Genetics preps filing next year for oral HER2 drug

Competition in the HER2 category is heating up though, with a new antibody-drug conjugate from Daiichi Sankyo and AstraZeneca –  trastuzumab deruxtecan – angling for approval in the US in the second

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]